Clinical Trial Update: Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies. [Phase 2]

View source ↗

Summary

This is an extension study evaluating long-term safety and efficacy of Myozyme (alglucosidase alfa) in a single patient with Pompe disease who previously partic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease Late-Onset, Glycogen Storage Disease Type II GSD II | Phase 2 | Status: COMPLETED